Presentations in this session:

10:20 TuOa0201    Abstract Powerpoint Small molecule HIV entry inhibitors targeting gp41 Jiang S.1, Lu H.1, Liu S.1, Zhao Q.1, He Y.1, Debnath A.K.1 1New York Blood Center, New York, United States of America

10:35 TuOa0202    Abstract Powerpoint Immune therapy of advanced HIV-1 infection by transduced autologous T helper cells expressing a peptide which inhibits viral entry. Results of a phase I pilot study. van Lunzen J.1, Glaunsinger T.1, Stahmer I.1, Kühlcke K.2, Schilz A.2, Stellbrink H.J.1, Mayr C.3, Dinauer N.4, Alexandrov A.4, von Laer D.5 1University Medical Center Eppendorf, Hamburg, Germany, 2EUFETS AG, Idar-Oberstein, Germany, 3Private Practice Seestrasse, Berlin, Germany, 4Fresenius Biotech AG, Bad Homburg, Germany, 5Georg-Speyer-Haus, Frankfurt, Germany

10:50 TuOa0203    Abstract Treatment with growth hormone leads to improvement in total and naïve CD4 lymphocyte recovery in HIV-infected subjects with incomplete immune reconstitution on HAART Smith K.1, Wang R.2, Bosch R.2, Margolis D.3, Tenorio A.1, Pollard R.4, Stocker V.5, Gross B.6, Frances I.6, Muurahainen N.7, ACTG 5174 Protocol Team A.5 1Rush University Medical Center, Chicago, United States of America, 2Harvard School of Public Health, Boston, United States of America, 3UT Southwestern Medical Center, Dallas, United States of America, 4UC Davis Medical Center, San Diego, United States of America, 5AACTG Operations Center, Silver Spring, United States of America, 6University of Michigan, Ann Arbor, United States of America, 7Serono, Inc, Rockland, United States of America

11:05 TuOa0204    Abstract Powerpoint Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857) McHale M.1, Abel S.1, Russell D.1, Gallagher J.1, van der Ryst E.1 1Pfizer Global Research and Development, Sandwich, United Kingdom

11:20 TuOa0205    Abstract Powerpoint SCH 417690: antiviral activity of a potent new CCR5 receptor antagonist Schuermann D.1, Pechardscheck C.1, Rouzier R.2, Nougarede R.2, Faetkenheuer G.3, Ochlast I.3, Raffi F.4, Hoffman C.5, Greaves W.6, Sansone A.6 1Charatie Hospital, Berlin, Germany, 2CentreCap, Montpellier, France, 3University of Cologne, Cologne, Germany, 4Biotrial/University Hospital, Nantes and Rennes, France, 5University of Kiel, Kiel, Germany, 6Schering Plough Research Institute, Kenilworth, New Jersey, United States of America

11:35 TuOa0206    Abstract Powerpoint Antiviral synergy between the CCR5 mAb PRO 140 and small-molecule CCR5 antagonists Murga J.1, Olson W.1, Pevear D.1 1Progenics Pharmaceuticals, Inc., Tarrytown, United States of America